Mereo BioPharma Group plc Financial Ratios
MREO|FY2025 SEC 10-K data
Includes DuPont ROE decomposition, profitability margins, liquidity ratios, solvency indicators, and earnings quality analysis. All ratios calculated from FY2025 SEC 10-K data.
Key Data Points
- Altman Z-Score -7.87 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
DuPont ROE Decomposition (FY2025)
Return on Equity
-102.4%
Profit Margin
-8375.6%
Net Income / Revenue
Asset Turnover
0.01
Revenue / Total Assets
Equity Multiplier
1.12
Total Assets / Equity
Composite: -102.4% (reported: -102.4%)
Profitability
Liquidity
Current Ratio
10.46
Quick Ratio
10.46
Solvency
Interest Coverage
-121.45
Efficiency
Asset Turnover
0.01
Inventory Turnover
-
Days Sales Outstanding
-
As of FY2025 · SEC 10-K · Updated Jun 27, 2026
Earnings Quality
Accrual Ratio
-17.8%
-4.2pp YoY
Earnings are primarily supported by operating cash flow.
This metric is for informational purposes only and does not constitute investment advice. Data sourced from SEC EDGAR filings; updates may be delayed.